BusinessWire · Dec 2025
Valink and Nona announced a strategic biologics discovery alliance branded 'Biology to Bispecific' to combine Nona’s antibodies with Valink’s LiliumX platform for bsADC discovery, with an initial focus on solid tumors.
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Valink Therapeutics is a University of Oxford spinout and private biotechnology company developing first-in-class bispecific antibody-drug conjugates (bsADCs) for oncology, using its LiliumX modular discovery platform and V-Gate target-gating approach.
Primary product
Bispecific antibody-drug conjugates (bsADCs) built with the LiliumX platform
Founded
2021
Headquarters
One Broadway, Cambridge, Massachusetts 02142, United States
Team size
20-30
Industry
Biotechnology Research
Sub-industry
Oncology therapeutics / bispecific antibody-drug conjugates
Offices
One Broadway, Cambridge, Massachusetts 02142, United States
Open Positions
0 jobs at Valink Therapeutics
No open positions
Check back later for new openings